About the Advanced Regenerative Manufacturing Institute
Our mission is to advance the bioeconomy of the United States. The Institute’s work will positively impact not only manufacturing but also healthcare and education and workforce development for the nation.
Manufacturing scalability, process and partnership.
There are 400,000 people worldwide right now on waiting lists for organs. What if we could create lungs, livers or corneas at scale? It would be unprecedented.
Our goal is to move highly specialized regenerative medicine – engineering or regenerating human cells, tissues and organs – from lab to production to cure diseases and improve quality of life.
ARMI’s Leadership Team
DEAN KAMEN
Executive Director & Chairman of the Board, ARMI
Maureen Toohey
Deputy Executive Director & Secretary of the Board
Thomas Bollenbach, Ph.D.
Chief Technology Officer
Jim Scott
Chief Administrative Officer
Jennifer MacDonald, M.D.
Chief Operating Officer
News Highlights
Events
Events
-
-
TERMIS-AM 2026
New Orleans, LouisianaARMI will attend TERMIS-AM 2026, the premier North American conference for tissue engineering and regenerative medicine, bringing together researchers, clinicians, industry leaders, and innovators advancing the future of regenerative therapies.
-
Automation Fair® 2026
Boston, MA Boston, MA, United StatesARMI plans to participate in Automation Fair® 2026, Rockwell Automation’s premier industrial operations event, bringing together manufacturing leaders, technology innovators, and automation experts to explore the future of smart manufacturing.
-
4th Annual BIO-SENS Industry & Academic Biotechnology Symposium
UNH Durham, NH, United StatesJoin industry and academic leaders at UNH on November 18 for a free symposium exploring protein sensing, process analytical technology, and biomanufacturing innovation. Poster and panel participation opportunities are available.
-
-
NIH-HESI Workshop: Assessing Emerging Cell and Gene Therapies for Disease-Specific Therapeutic Applications
HybridARMI Chief Regulatory Officer Dr. Richard McFarland will moderate a panel at the NIH-HESI workshop, December 2–3, 2026. This hybrid event explores in vivo tracking, biodistribution, regulatory considerations, and emerging technologies for cell and gene therapies.
